A Single-centre, Randomized, Placebo-controlled, Double-blind, Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Contraloid (Primary)
- Indications Mild cognitive impairment
- Focus Adverse reactions
Most Recent Events
- 22 Aug 2022 Status changed from recruiting to completed.
- 04 Aug 2022 Results presented at the Alzheimer's Association International Conference 2022
- 20 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Nov 2021.